( A - C ) 25 g/L/mouse IgG1 (n=5), 1 g/L/mouse mGIPR-Ab/P3 (n=6), 5 g/L/mouse mGIPR-Ab/P3 (n=6), 10 g/L/mouse mGIPR-Ab/P3 (n=6), or 25 g/L/mouse mGIPR-Ab/P3 (n=6)
Compared to usual care, GLP-1RA use was associated with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions
also, lipids and C-reactive protein levels increased by week 120, yet maintaining a significant difference with respect to patients on placebo 77
Lots of them, in fact, that can support you on your wellness journey as your estrogen and progesterone levels begin their rocky decline